You can edit almost every page by Creating an account. Otherwise, see the FAQ.

Hookipa Biotech

From EverybodyWiki Bios & Wiki


Hookipa Biotech AG (Hookipa) is an Austrian clinical stage biotechnology company founded on July 8, 2011 and headquartered at the Vienna BioCenter in Vienna, Austria. Hookipa aims to develop active immunization therapies for infectious diseases and oncology with its proprietary TheraT® and Vaxwave® viral vector platforms. The pillars of the company revolve around a discovery for which Founder Prof Rolf Zinkernagel was awarded a Nobel Prize.[1] In 2017 Hookipa opened a US site at the Alexandria LaunchLabs® in New York.[2] As of February 2018, the Hookipa team consists of 51 employees.[3]

Timeline [4][edit]

  • 2011 Oct 17th Hookipa Biotech closes € 7 million Series A Financing
  • 2012 Sep 18th Hookipa is awarded a grant from the Austrian Research Promotion Agency for development of its first vaccine candidate HB101
  • 2013 Nov 4th Hookipa Biotech closes € 20 million ($ 27.5 million) in Series B Financing
  • 2014 March 31st Hookipa Biotech Wins Best Financing Deal Award in the Vaccine Industry Excellence (ViE) Awards 2014
  • 2014 April 22nd Hookipa receives additional grant support from FFG for development of vaccine candidate HB101
  • 2014 Aug 27th Appointment of John Lambert to Chairman of Board of Directors
  • 2016 June 16th Appointment of Joern Aldag to CEO
  • 2016 July 20th Hookipa Biotech Initiates First-in-Human Study of Cytomegalovirus Vaccine
  • 2016 Oct 17th Hookipa Secures Additional Grant Support from the Austrian Research Promotion Agency to Develop Arenavirus Vector-Based Cancer Immunotherapies
  • 2017 Jan 9th Hookipa Biotech Announces Publication in Clinical and Vaccine Immunology Highlighting Vaxwave® as an Effective Viral Vector for Vaccination against Congenital Cytomegalovirus Infections
  • 2017 March 6th Appointment of Igor Matushansky to Global Head Research and Development
  • 2017 April 18th Appointment of Reinhard Kandera to CFO
  • 2017 May 4th Hookipa Biotech presents positive data from Phase 1 first-in-human trial of vaccine against cytomegalovirus
  • 2017 May 26th Hookipa Biotech Announces Nature Communications Publication Showing TheraT® Turns Cold Tumors Hot
  • 2017 Dec Hookipa Biotech Raises $60 million (€50 million) in an Oversubscribed Round C Financing
  • 2018 26 March Hookipa Presents New Phase 1 Data for HB-101 at the World Vaccine Congress
  • 2018 07 May Hookipa Shortlisted for European Mediscience Award 2018
  • 2018 15 May Hookipa´s TheraT Replicating Viral Vector Platform published in Immunity


  1. Hookipa Biotech AG. "Our Difference". Retrieved February 20, 2018.
  2. Xconomy (article by Ben Fidler). "Alexandria Debuts NY's Latest Bio Incubator With 13 Startups in Tow". Retrieved March 6, 2018.
  3. LISAvienna - Life Science Austria Vienna. "Innovation made in Vienna: Hookipa Biotech is supercharging immunotherapies with $60 million" (PDF). Retrieved March 6, 2018.
  4. Hookipa Biotech AG. "News & Events". Retrieved February 20, 2018.

This article "Hookipa Biotech" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Hookipa Biotech. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.